This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Efficacy, Safety, and Tolerability of Multiple Dos...
Clinical trial

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Read time: 3 mins
Last updated:6th Sep 2016
Identifier: NCT02848326

This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.

Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 834 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Actual Study Start Date: September 6, 2016
Actual Primary Completion Date: April 2, 2018
Actual Study Completion Date: April 23, 2018

- Placebo Comparator:
- Experimental: Atogepant 10 mg QD
- Experimental: Atogepant 30 mg QD
- Experimental: Atogepant 30 mg BID
- Experimental: Atogepant 60 mg QD
- Experimental: Atogepant 60 mg BID

Category Value
Date last updated at source 2018-12-06
Study type(s) Interventional
Expected enrolment 834
Study start date 2016-09-06
Estimated primary completion date 2018-04-02

View full details